Log in

NASDAQ:GNCA - Genocea Biosciences Stock Price, Forecast & News

$2.20
-0.06 (-2.65 %)
(As of 01/24/2020 04:00 PM ET)
Today's Range
$2.16
Now: $2.20
$2.38
50-Day Range
$2.05
MA: $2.24
$2.73
52-Week Range
$1.99
Now: $2.20
$11.28
Volume181,223 shs
Average Volume187,911 shs
Market Capitalization$57.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.61 per share

Profitability

Net Income$-27,810,000.00

Miscellaneous

Employees61
Market Cap$57.53 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.


Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences Inc (NASDAQ:GNCA) announced its quarterly earnings data on Thursday, October, 24th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.17. View Genocea Biosciences' Earnings History.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Genocea Biosciences.

What price target have analysts set for GNCA?

5 equities research analysts have issued 12-month target prices for Genocea Biosciences' stock. Their forecasts range from $7.00 to $32.00. On average, they expect Genocea Biosciences' stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 642.4% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.

What is the consensus analysts' recommendation for Genocea Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.

What are Wall Street analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:
  • 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (12/24/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are lowering our price target to $32 from $42 to reflect the recent dilution, and fully diluted share count from the company’s equity raise." (7/25/2019)

Has Genocea Biosciences been receiving favorable news coverage?

Media headlines about GNCA stock have trended very negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genocea Biosciences earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Genocea Biosciences.

Are investors shorting Genocea Biosciences?

Genocea Biosciences saw a increase in short interest in December. As of December 31st, there was short interest totalling 97,500 shares, an increase of 18.5% from the December 15th total of 82,300 shares. Based on an average daily trading volume, of 132,900 shares, the short-interest ratio is currently 0.7 days. Currently, 0.7% of the company's shares are sold short. View Genocea Biosciences' Current Options Chain.

Who are some of Genocea Biosciences' key competitors?

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Hudson Technologies (HDSN), Micron Technology (MU), Accenture (ACN) and AutoZone (AZO).

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the folowing people:
  • Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
  • Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)
  • Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
  • Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
  • Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55)

Who are Genocea Biosciences' major shareholders?

Genocea Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (1.05%) and Wedbush Securities Inc. (0.07%). Company insiders that own Genocea Biosciences stock include George Siber, Michael Alfieri and Peter W Sonsini. View Institutional Ownership Trends for Genocea Biosciences.

Which major investors are buying Genocea Biosciences stock?

GNCA stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC and Wedbush Securities Inc.. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri and Peter W Sonsini. View Insider Buying and Selling for Genocea Biosciences.

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $2.20.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $57.53 million. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.View Additional Information About Genocea Biosciences.

What is Genocea Biosciences' official website?

The official website for Genocea Biosciences is http://www.genocea.com/.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]


MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  342 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  605
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel